Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» July 2011
July 2011
Lannett Drops After FDA Approval With More Decisions Pending
Lannett Drops After FDA Approval With More Decisions Pending
Seeking Alpha
FDA
Lannett
morphine sulfate
4-Star Stocks Poised to Pop: Merck
4-Star Stocks Poised to Pop: Merck
Motley Fool
Merck
Dentsply Acquisition Delivers Smiles
Dentsply Acquisition Delivers Smiles
Motley Fool
M&A
Dentsply
AstraZeneca
dental
Astra Tech
Dendreon climbs 4% in premarket trading
Dendreon climbs 4% in premarket trading
Marketwatch
Medicare
Dendreon
Provenge
prostate cancer
[video] The Next Big Thing In Biotech: Seattle Genetics
[video] The Next Big Thing In Biotech: Seattle Genetics
TheStreet.com
Seattle Genetics
7 Rallying Biotech Stocks With Conservative Accounting Practices
7 Rallying Biotech Stocks With Conservative Accounting Practices
Seeking Alpha
Acorda Therapeutics
Incyte
Chelsea Therapeutics
Regeneron
Spectrum Pharmaceuticals
Jazz Pharmaceuticals
Neurocrine
Medicare Will Continue to Cover 2 Expensive Cancer Drugs
Medicare Will Continue to Cover 2 Expensive Cancer Drugs
NY Times, NY
Medicare
Provenge
prostate cancer
Dendreon
Roche
Avastin
breast cancer
Cramer Interviews Celgene CEO Hugin
Cramer Interviews Celgene CEO Hugin
CNBC
Celgene
Pharma CEOs
Bob Hugin
Merck says Gardasil, Cubicin approved in Japan
Merck says Gardasil, Cubicin approved in Japan
Yahoo/AP
Gardasil
Japan
Merck
Cubicin
Cubist Pharmaceuticals
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review
Motley Fool
FDA
Bristol-Myers Squibb
AstraZeneca
Pfizer
Incyte
Novartis
ruxolitinib
Apixaban
Dapagliflozin
Pages
« first
‹ previous
…
38
39
40
41
42
43
44
45
46